NK105, a paclitaxel-incorporating micellar nanoparticle formulation, can extend in vivo antitumour activity and reduce the neurotoxicity of paclitaxel.

Hamaguchi T, Matsumura Y, Suzuki M, Shimizu K, Goda R, Nakamura I, Nakatomi I, Yokoyama M, Kataoka K, Kakizoe T. · 2005

Read NK105, a paclitaxel-incorporating micellar nanoparticle formulation, can extend in vivo antitumour activity and reduce the neurotoxicity of paclitaxel. by Hamaguchi T, Matsumura Y, Suzuki M, Shimizu K, Goda R, Nakamura I, Nakatomi I, Yokoyama M, Kataoka K, Kakizoe T. (2005) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc2361981.txt.

Description

Hamaguchi and co-authors tested a new delivery form of the cancer drug paclitaxel in 2005. Paclitaxel kills many cancers but causes nerve damage, low blood counts, and allergic reactions, partly from the solvent used to dissolve it. Their version, NK105, tucks the drug inside tiny polymer spheres called micelles.

In animal tests, NK105 kept drug levels in blood about 90 times higher than the free drug, because the spheres leaked little and dodged body filters. Tumor levels ran 25 times higher, thanks to the spheres gathering in tumor tissue. Against human colon cancer grafts, NK105 shrank tumors far better than free paclitaxel. Nerve damage was clearly weaker too, shown by both tissue checks and nerve function tests. The authors said patient trials were warranted.

Catalog record

CREATORHamaguchi T, Matsumura Y, Suzuki M, Shimizu K, Goda R, Nakamura I, Nakatomi I, Yokoyama M, Kataoka K, Kakizoe T.
YEAR2005
COLLECTIONPAPERS
FORMATTXT
FILE SIZE32 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC2361981

Browse the full library · About the Tower of Babel